Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial - The Lancet Oncology
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial - ESMO Open
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma | NEJM
Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma | British Journal of Cancer
Sunitinib maleate | Nature Reviews Drug Discovery
Sunitinib: the antiangiogenic effects and beyond | OTT
Real-world Experience With Sunitinib Treatment in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to Risk Score - Clinical Genitourinary Cancer
Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features | Journal of Clinical Oncology
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma | NEJM
Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial - The Lancet Oncology
Sunitinib ongoing clinical trials. | Download Scientific Diagram
Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma - ScienceDirect
Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC - Clinical Genitourinary Cancer
Efficacy results of Phase III clinical trials comparing immune... | Download Scientific Diagram
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | NEJM
Clinical response to sunitinib as a multitargeted tyrosine-kinase inhi | OTT
Selected clinical trials investigating sunitinib in pancreatic... | Download Scientific Diagram
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | NEJM
Sunitinib objective response in metastatic renal cell carcinoma: Analysis of 1059 patients treated on clinical trials - European Journal of Cancer
Selected clinical trials of sunitinib. GIST, gastrointestinal stromal... | Download Table
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial - The Lancet Oncology
Clinical benefit of sunitinib in the phase I/II trial in imatinib... | Download Table
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial - The Lancet
Sunitinib shows efficacy in pheochromocytoma and paraganglioma
CANCER CLINICAL TRIALS - Argos Therapeutics
